Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Other Operating Expenses (2018 - 2024)

Historic Other Operating Expenses for Ascendis Pharma A (ASND) over the last 7 years, with Q4 2024 value amounting to $139.5 million.

  • Ascendis Pharma A's Other Operating Expenses rose 16136.73% to $139.5 million in Q4 2024 from the same period last year, while for Sep 2025 it was $139.5 million, marking a year-over-year increase of 16136.73%. This contributed to the annual value of $608.2 million for FY2024, which is 904.95% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Other Operating Expenses of $139.5 million as of Q4 2024, which was up 16136.73% from -$227.3 million recorded in Q4 2023.
  • Ascendis Pharma A's 5-year Other Operating Expenses high stood at $139.5 million for Q4 2024, and its period low was -$773.7 million during Q4 2020.
  • Moreover, its 5-year median value for Other Operating Expenses was -$262.9 million (2021), whereas its average is -$278.1 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 9247.37% in 2020, then skyrocketed by 16136.73% in 2024.
  • Ascendis Pharma A's Other Operating Expenses (Quarter) stood at -$773.7 million in 2020, then skyrocketed by 66.02% to -$262.9 million in 2021, then fell by 1.14% to -$265.9 million in 2022, then rose by 14.54% to -$227.3 million in 2023, then surged by 161.37% to $139.5 million in 2024.
  • Its Other Operating Expenses was $139.5 million in Q4 2024, compared to -$227.3 million in Q4 2023 and -$265.9 million in Q4 2022.